Market Overview:
The global plasminogen activator inhibitor 1 market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of thrombotic disorders and acute ischemic stroke, rising geriatric population, and technological advancements in plasminogen activator inhibitor 1 therapies. However, the high cost of treatment and lack of awareness about these therapies are likely to restrain the growth of this market during the forecast period. Based on type, SK-216 accounted for a major share of the global plasminogen activator inhibitor 1 market in 2017. This can be attributed to its high efficacy and safety profile as compared to other types available in the market. By application, thrombosis held a dominant share of the global plasminogen activator inhibitor 1 market in 2017 owing to its widespread use across various indications such as myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), and others.
Product Definition:
The plasminogen activator inhibitor-1 (PAI-1) is a protein that inhibits the activity of the plasminogen activator enzyme. PAI-1 is important in regulating fibrinolysis, the process by which fibrin is broken down to release individual blood clots. Elevated levels of PAI-1 can lead to an increased risk of thrombosis (formation of blood clots).
SK-216:
Plasminogen activator inhibitor (PAI) is a protein that inhibits the activity of the plasminogen activator, which is responsible for the activation of plasminogen to form a curative clot. The inhibition of PAI results in increased blood flow and hence more oxygen delivered to tissues. Increased tissue oxygenation leads to an enhanced performance and recovery from exercise-induced fatigue by enhancing muscle endurance.
THR-18:
Thrombolytic agents are used to dissolve clots in the blood vessels and prevent further damage. The most commonly used thrombolytic agent is t-PA (Plasminogen Activator). It works by breaking down the fibrin network that holds blood cells in place, allowing them to flow through the vessel easily. In addition, it helps remove debris from blocked arteries and veins.
The global thrombolytic market was valued at USD 3.
Application Insights:
Acute ischemic stroke accounted for the largest share of 23.3% in terms of revenue in 2017. The segment is anticipated to witness lucrative growth during the forecast period due to rising incidence rates of acute ischemic stroke around the world. According to a study conducted by WHO, it was estimated that approximately 60 million people suffered from this condition globally and about half of them were under 60 years old. In addition, another study reported that out of all deaths caused by cerebral infarction, 29% occurred in low- and middle-income countries where there was no existing treatment option available for this purpose until date. Thus, increasing incidences are expected to boost product demand over the forecast period (see table below).
Plasminogen activator inhibitor indicates use within 24 hours prior to admission into an intensive care unit (ICU) reduces mortality rate associated with acute kidney failure caused by severe trauma or burns.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the major factors responsible for its growth. In addition, a rise in cases of acute ischemic stroke has also been observed in this region which is one of the high impact rendering drivers for this regional market. CT-140 (reteplase) was approved by the U.S FDA in 2015 under emergency use authorization process for treatment of acute ischemic stroke within 6 hours after onset as judged from symptom onset to computed tomography confirmation or until suitable therapy judged appropriate by qualified physician(s).
Asia Pacific plasminogen activator inhibitor 1 market is expected to grow at a lucrative rate over the forecast period owing to various factors such as rising geriatric population prone to cardiovascular diseases.
Growth Factors:
- Increasing incidence of cardiovascular diseases: The increasing incidence of cardiovascular diseases is one of the key growth drivers for the plasminogen activator inhibitor 1 market. According to a study by the World Health Organization (WHO), an estimated 17.9 million people died from cardiovascular diseases in 2012, accounting for 31% of all global deaths. This number is expected to increase to 23.3 million by 2030. This will create a high demand for plasminogen activator inhibitor 1 drugs and therapies, thereby driving the growth of the market.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to drive the demand for plasminogen activator inhibitor 1 drugs and therapies in the coming years. According to estimates by United Nations, there were 841 million people aged 60 or above in 2015 and this number is projected to reach 2 billion by 2050. This will create a high need for effective treatments against age-related disorders such as heart attacks and strokes, which will boost the growth of Plasminogen Activator Inhibitor 1 market during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Plasminogen Activator Inhibitor 1 Market Research Report
By Type
SK-216, THR-18, Defibrotide Sodium, CT-140, Others
By Application
Thrombosis, Acute Ischemic Stroke, Arterial Thrombosis, Hypertension, Others
By Companies
D-Pharm Ltd, Jazz Pharmaceuticals Plc, D-Pharm Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
180
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Plasminogen Activator Inhibitor 1 Market Report Segments:
The global Plasminogen Activator Inhibitor 1 market is segmented on the basis of:
Types
SK-216, THR-18, Defibrotide Sodium, CT-140, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Thrombosis, Acute Ischemic Stroke, Arterial Thrombosis, Hypertension, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- D-Pharm Ltd
- Jazz Pharmaceuticals Plc
- D-Pharm Ltd
Highlights of The Plasminogen Activator Inhibitor 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- SK-216
- THR-18
- Defibrotide Sodium
- CT-140
- Others
- By Application:
- Thrombosis
- Acute Ischemic Stroke
- Arterial Thrombosis
- Hypertension
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plasminogen Activator Inhibitor 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plasminogen activator inhibitor 1 (PAI-1) is a protein that inhibits the activity of plasminogen. PAI-1 is found in the blood and other tissues, and can stop the clotting process that helps wounds heal.
Some of the key players operating in the plasminogen activator inhibitor 1 market are D-Pharm Ltd, Jazz Pharmaceuticals Plc, D-Pharm Ltd.
The plasminogen activator inhibitor 1 market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Plasminogen Activator Inhibitor 1 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Plasminogen Activator Inhibitor 1 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Plasminogen Activator Inhibitor 1 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Plasminogen Activator Inhibitor 1 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Plasminogen Activator Inhibitor 1 Market Size & Forecast, 2020-2028
4.5.1 Plasminogen Activator Inhibitor 1 Market Size and Y-o-Y Growth
4.5.2 Plasminogen Activator Inhibitor 1 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 SK-216
5.2.2 THR-18
5.2.3 Defibrotide Sodium
5.2.4 CT-140
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Thrombosis
6.2.2 Acute Ischemic Stroke
6.2.3 Arterial Thrombosis
6.2.4 Hypertension
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Plasminogen Activator Inhibitor 1 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Plasminogen Activator Inhibitor 1 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 SK-216
9.6.2 THR-18
9.6.3 Defibrotide Sodium
9.6.4 CT-140
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Thrombosis
9.10.2 Acute Ischemic Stroke
9.10.3 Arterial Thrombosis
9.10.4 Hypertension
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 SK-216
10.6.2 THR-18
10.6.3 Defibrotide Sodium
10.6.4 CT-140
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Thrombosis
10.10.2 Acute Ischemic Stroke
10.10.3 Arterial Thrombosis
10.10.4 Hypertension
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 SK-216
11.6.2 THR-18
11.6.3 Defibrotide Sodium
11.6.4 CT-140
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Thrombosis
11.10.2 Acute Ischemic Stroke
11.10.3 Arterial Thrombosis
11.10.4 Hypertension
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 SK-216
12.6.2 THR-18
12.6.3 Defibrotide Sodium
12.6.4 CT-140
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Thrombosis
12.10.2 Acute Ischemic Stroke
12.10.3 Arterial Thrombosis
12.10.4 Hypertension
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 SK-216
13.6.2 THR-18
13.6.3 Defibrotide Sodium
13.6.4 CT-140
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Thrombosis
13.10.2 Acute Ischemic Stroke
13.10.3 Arterial Thrombosis
13.10.4 Hypertension
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Plasminogen Activator Inhibitor 1 Market: Competitive Dashboard
14.2 Global Plasminogen Activator Inhibitor 1 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 D-Pharm Ltd
14.3.2 Jazz Pharmaceuticals Plc
14.3.3 D-Pharm Ltd
